A Rs 1600 crore group, Surya Corp is an integrated group of companies, with diversified interests in pharmaceuticals, healthcare, education, pharmacy retail and beverages. Headquartered in Chandigarh, its companies have rapidly emerged as leaders across all its businesses and have gradually established a global footprint with acquisitions and customers in more than 90 countries. The rapid expansion of the group has been driven by its commitment towards empowering life in all facets of human well-being and development. It is an A listed and certified organization with a personnel base of nearly 6000 dedicated and motivated employees.
Its flagship company, Surya Pharmaceutical Limited (SPL) has already demonstrated astounding business growth by acquisition of Family First Pharmaceutical Co. in the US. SPL also ranks in the top Fortune India 500 companies, being the 20th largest Pharmaceutical firm as well as one of ET 500 and BS 500 companies in India. SPL crossed an important milestone recently when it launched its super specialty Neuropsychiatric division called ALVIN.
Interacting with media persons, Mr Rajiv Goyal, Chairman & Managing Director, Surya Pharmaceutical Limited (SPL) said, “ALVIN is the sixth division of the formulation division of Surya Pharmaceutical Limited. We started formulation division in December, 2009 and achieved topline of Rs 15 cr by March 2011 and expect to achieve topline of Rs 50 cr during 2011-12.The earlier existing five divisions include Alexus (general products); Altair (diagnostic and medical equipment); Adonia (gynae care), Acucare (critical care) and Aegis (generic formulations). SPL is also launching shortly its seventh division, Auskin which will be dedicated to skin care.”
Generally sharing about the potential of the Neuropsychiatry market, Mr Goyal stated, “ The size of the Neuropsychiatry market in India is Rs 3000 crore which is growing at the rate of 15% annually. Surya has entered into the domain of Neuropsychiatry with a view to leverage this potential and with the launch of ALVIN, Surya is targeting sale of Rs 15 crore in the first year, Rs 26 crore in the second year and Rs 40 crore in the third year respectively. “The major therapeutic segments being covered under the division are anti-epileptic, anti-depressant, anti-psychotic, anti-migraine, Anxiolytic & sexual dysfunction, Prokinetic etc,” said Mr Goyal.
Talking about the business strategy Mr Goyal said, “ALVIN has been launched at 120 headquarters with 160 sales professionals on pan India basis and will be covering around 15000 leading neurologists, psychiatrists & neuro-physicians. In the first phase, ALVIN is coming up with 15 major neuropsychiatric molecules which include Escitalopram, Mirtazapine, Divalproex, Levetiracetam, Oxcarbezapine, Dapoxetine, olanzapine, Clonazepam etc and also planning to launch two formulations for the first time in India (Escitalopram + Olanzapine & Dapoxetine + Sildenafil) in the second phase.”